Ryan Andrew M, Krinsky Sam, Maurer Kristin A, Dimick Justin B
From the Department of Health Management and Policy, University of Michigan School of Public Health (A.M.R., S.K., K.A.M.), and the Department of Surgery, University of Michigan Medical School (J.B.D.) - both in Ann Arbor.
N Engl J Med. 2017 Jun 15;376(24):2358-2366. doi: 10.1056/NEJMsa1613412.
Starting in fiscal year 2013, the Hospital Value-Based Purchasing (HVBP) program introduced quality performance-based adjustments of up to 1% to Medicare reimbursements for acute care hospitals.
We evaluated whether quality improved more in acute care hospitals that were exposed to HVBP than in control hospitals (Critical Access Hospitals, which were not exposed to HVBP). The measures of quality were composite measures of clinical process and patient experience (measured in units of standard deviations, with a value of 1 indicating performance that was 1 standard deviation [SD] above the hospital mean) and 30-day risk-standardized mortality among patients who were admitted to the hospital for acute myocardial infarction, heart failure, or pneumonia. The changes in quality measures after the introduction of HVBP were assessed for matched samples of acute care hospitals (the number of hospitals included in the analyses ranged from 1364 for mortality among patients admitted for acute myocardial infarction to 2615 for mortality among patients admitted for pneumonia) and control hospitals (number of hospitals ranged from 31 to 617). Matching was based on preintervention performance with regard to the quality measures. We evaluated performance over the first 4 years of HVBP.
Improvements in clinical-process and patient-experience measures were not significantly greater among hospitals exposed to HVBP than among control hospitals, with difference-in-differences estimates of 0.079 SD (95% confidence interval [CI], -0.140 to 0.299) for clinical process and -0.092 SD (95% CI, -0.307 to 0.122) for patient experience. HVBP was not associated with significant reductions in mortality among patients who were admitted for acute myocardial infarction (difference-in-differences estimate, -0.282 percentage points [95% CI, -1.715 to 1.152]) or heart failure (-0.212 percentage points [95% CI, -0.532 to 0.108]), but it was associated with a significant reduction in mortality among patients who were admitted for pneumonia (-0.431 percentage points [95% CI, -0.714 to -0.148]).
In our study, HVBP was not associated with improvements in measures of clinical process or patient experience and was not associated with significant reductions in two of three mortality measures. (Funded by the National Institute on Aging.).
从2013财年开始,医院价值导向型采购(HVBP)计划对急性护理医院的医疗保险报销引入了高达1%的基于质量绩效的调整。
我们评估了与对照医院(未参与HVBP的临界接入医院)相比,参与HVBP的急性护理医院的质量改善是否更大。质量指标包括临床过程和患者体验的综合指标(以标准差为单位衡量,值为1表示绩效比医院平均水平高1个标准差[SD]),以及因急性心肌梗死、心力衰竭或肺炎入院的患者30天风险标准化死亡率。在对急性护理医院(分析中纳入的医院数量从急性心肌梗死入院患者死亡率分析中的1364家到肺炎入院患者死亡率分析中的2615家不等)和对照医院(医院数量从31家到617家不等)的匹配样本中,评估引入HVBP后质量指标的变化。匹配基于干预前质量指标的表现。我们评估了HVBP前4年的绩效情况。
参与HVBP的医院在临床过程和患者体验指标方面的改善并不显著高于对照医院,临床过程的差异差值估计为0.079 SD(95%置信区间[CI],-0.140至0.299),患者体验的差异差值估计为-0.092 SD(95% CI,-0.307至0.122)。HVBP与急性心肌梗死入院患者死亡率的显著降低无关(差异差值估计,-0.282个百分点[95% CI,-1.715至1.152])或心力衰竭患者死亡率的显著降低无关(-0.212个百分点[95% CI,-0.532至0.108]),但与肺炎入院患者死亡率的显著降低有关(-0.431个百分点[95% CI,-0.714至-0.148])。
在我们的研究中,HVBP与临床过程指标或患者体验的改善无关,并且与三项死亡率指标中的两项显著降低无关。(由美国国立衰老研究所资助。)